A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes

Figures & data

Figure 1. Genes differentially expressed between diagnosis and relapse of CN AML. Log₂ fold changes compared to the mean of all samples are displayed for the 30 most up- and the 30 most down-regulated genes (i.e. significantly differentially expressed genes with the highest positive and negative mean log₂ fold changes between the two disease states). Red, gene expression above the mean; blue, gene expression below the mean. DG, diagnosis; R, relapse.

Figure 2. Gene signatures associated with LSCs, HSCs and poor therapy response are enriched in the CN AML relapse profile. Lists of genes associated with functionally defined LSCs [7], cell surface marker-defined HSCs [7], poor response to chemotherapy [10–12] or marker-defined LSCs [9] were probed against the relapse-associated gene expression profile, ranked according to each gene's associated t-statistic, using gene set enrichment analysis (GSEA) [8]. The number of genes present in the relapse profile, as well as the total number of genes, is indicated for each signature. NES, normalized enrichment score; FDR, false discovery rate. Similar results were obtained when genes were ranked according to their log₂ fold change between the two disease states.

Eppert K, Takenaka K, Lechman E, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086–1093.

 PubMed Web of Science ®Google Scholar

Gentles A, Plevritis S, Majeti R, et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010;304:2706–2715.

 PubMed Web of Science ®Google Scholar

Subramanian A, Tamayo P, Mootha V, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545–15550.

 PubMed Web of Science ®Google Scholar